Structure Therapeutics Inc ADRGPCR
Price$28.98

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$214.8MTTM through 30 Jun 2026
Free Cash Flow -$224.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-5.3%ROE
-5.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio24.81x
Net Debt-$1.5Bnet cash position
Cash & Equivalents$272.6M

Quality Metrics

Altman Z-Score22.10
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Diluted EPS-$1.01TTM
'22'23'24'25
FY2025: $-0.80

Dividend

No dividend

Capital Allocation

R&D Spend$294.2M

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Research and Development$0
View details

Phase 3 registrational program for chronic weight management is on track to initiate in Q3 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.